Insecticides India Ltd
Insecticides India is into manufacturing of agrochemicals (technicals and formulations) and biological and household products. They cater to Indian market where they directly sell to the end consumer and also sell technicals and formulations to the companies who are in the business of formulation. They also export to 30 countries with more than 100 customers through registrations. IIL has more than 75 registrations so far.[1]
- Market Cap ₹ 2,090 Cr.
- Current Price ₹ 706
- High / Low ₹ 1,085 / 460
- Stock P/E 15.9
- Book Value ₹ 377
- Dividend Yield 0.42 %
- ROCE 13.0 %
- ROE 10.5 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 10.5% over past five years.
- Company has a low return on equity of 10.1% over last 3 years.
- Dividend payout has been low at 9.43% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Agro Chemicals Industry: Pesticides / Agrochemicals - Indian
Part of BSE Allcap BSE Commodities BSE SmallCap
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
566 | 801 | 892 | 906 | 994 | 1,073 | 1,194 | 1,363 | 1,420 | 1,504 | 1,801 | 1,966 | 1,914 | |
498 | 719 | 781 | 815 | 880 | 925 | 1,006 | 1,207 | 1,268 | 1,333 | 1,679 | 1,803 | 1,717 | |
Operating Profit | 68 | 82 | 111 | 91 | 114 | 148 | 188 | 156 | 153 | 171 | 122 | 163 | 197 |
OPM % | 12% | 10% | 12% | 10% | 11% | 14% | 16% | 11% | 11% | 11% | 7% | 8% | 10% |
1 | 0 | 0 | 0 | 4 | 3 | 0 | 2 | -2 | 3 | 1 | 10 | 10 | |
Interest | 17 | 27 | 33 | 26 | 20 | 16 | 15 | 24 | 7 | 7 | 13 | 11 | 8 |
Depreciation | 6 | 7 | 14 | 16 | 16 | 17 | 20 | 24 | 25 | 26 | 26 | 29 | 29 |
Profit before tax | 46 | 49 | 64 | 50 | 82 | 118 | 153 | 110 | 119 | 141 | 84 | 133 | 169 |
Tax % | 24% | 18% | 15% | 21% | 28% | 29% | 20% | 22% | 22% | 24% | 25% | 23% | |
35 | 40 | 55 | 39 | 59 | 84 | 122 | 86 | 93 | 107 | 63 | 103 | 131 | |
EPS in Rs | 12.39 | 14.01 | 19.24 | 12.67 | 19.16 | 27.09 | 39.49 | 27.75 | 30.14 | 36.16 | 21.28 | 34.67 | 44.29 |
Dividend Payout % | 11% | 10% | 0% | 11% | 7% | 5% | 3% | 10% | 4% | 6% | 14% | 9% |
Compounded Sales Growth | |
---|---|
10 Years: | 9% |
5 Years: | 11% |
3 Years: | 11% |
TTM: | -4% |
Compounded Profit Growth | |
---|---|
10 Years: | 10% |
5 Years: | -4% |
3 Years: | 0% |
TTM: | 109% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 15% |
3 Years: | 18% |
1 Year: | 16% |
Return on Equity | |
---|---|
10 Years: | 13% |
5 Years: | 11% |
3 Years: | 10% |
Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Sep 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 13 | 13 | 13 | 21 | 21 | 21 | 21 | 21 | 21 | 20 | 30 | 30 | 30 |
Reserves | 200 | 234 | 279 | 388 | 444 | 527 | 641 | 710 | 798 | 847 | 886 | 982 | 1,087 |
211 | 258 | 322 | 206 | 237 | 114 | 305 | 191 | 100 | 54 | 163 | 87 | 66 | |
209 | 287 | 308 | 322 | 277 | 338 | 388 | 372 | 505 | 473 | 615 | 611 | 627 | |
Total Liabilities | 632 | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,809 |
140 | 170 | 205 | 194 | 185 | 232 | 240 | 239 | 239 | 253 | 262 | 283 | 293 | |
CWIP | 45 | 54 | 38 | 51 | 58 | 17 | 19 | 39 | 59 | 91 | 123 | 141 | 136 |
Investments | 0 | 11 | 11 | 11 | 11 | 16 | 12 | 10 | 12 | 13 | 15 | 19 | 21 |
447 | 556 | 667 | 680 | 725 | 735 | 1,084 | 1,004 | 1,115 | 1,037 | 1,293 | 1,267 | 1,359 | |
Total Assets | 632 | 791 | 921 | 936 | 978 | 1,000 | 1,355 | 1,293 | 1,424 | 1,394 | 1,694 | 1,710 | 1,809 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
-1 | 38 | -6 | 85 | 4 | 182 | -133 | 242 | 155 | 135 | -11 | 185 | |
-46 | -57 | -33 | -19 | -14 | -26 | -49 | -24 | -113 | 9 | -87 | -44 | |
35 | 23 | 36 | -63 | 9 | -143 | 172 | -159 | -104 | -115 | 80 | -98 | |
Net Cash Flow | -13 | 4 | -2 | 3 | -0 | 13 | -11 | 59 | -61 | 30 | -18 | 43 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 75 | 58 | 68 | 84 | 78 | 80 | 75 | 86 | 65 | 70 | 60 | 55 |
Inventory Days | 221 | 189 | 220 | 190 | 232 | 214 | 355 | 202 | 248 | 228 | 247 | 220 |
Days Payable | 128 | 124 | 118 | 114 | 108 | 128 | 141 | 96 | 136 | 117 | 128 | 114 |
Cash Conversion Cycle | 168 | 124 | 170 | 159 | 201 | 166 | 289 | 192 | 177 | 181 | 178 | 161 |
Working Capital Days | 147 | 115 | 138 | 137 | 155 | 126 | 206 | 147 | 132 | 123 | 124 | 109 |
ROCE % | 16% | 16% | 17% | 12% | 16% | 20% | 21% | 14% | 15% | 16% | 10% | 13% |
Documents
Announcements
-
Intimation Of Receipt Of PATENT (FUNGICIDAL COMPOSITIONS AND METHODS RELATED THERETO)
18h - Patent granted for fungicidal compositions for 20 years.
-
Announcement under Regulation 30 (LODR)-Earnings Call Transcript
15 Nov - Transcript of the Earning Conference Call for the Quarter and Half year ended September 30, 2024
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Of One-on-one and group meeting of Analyst / Institutional Investor under the SEBI (LODR), Regulations 2015 to be held from 10:00 AM to 5:00 PM …
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
12 Nov - Schedule of Analyst/Investor meetings on November 18, 2024.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
12 Nov - Audio recording of Q2 and H1 earnings call available.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from nse
-
Financial Year 2011
from bse
Concalls
-
Nov 2024Transcript PPT
-
Aug 2024Transcript PPT
-
Jun 2024Transcript PPT
-
May 2024TranscriptNotesPPT
-
Feb 2024Transcript PPT REC
-
Nov 2023Transcript PPT REC
-
Aug 2023Transcript PPT
-
Jun 2023Transcript PPT REC
-
Feb 2023Transcript PPT
-
Dec 2022TranscriptNotesPPT
-
Nov 2022Transcript PPT
-
Aug 2022Transcript PPT
-
May 2022TranscriptNotesPPT
-
Feb 2022TranscriptNotesPPT
-
Nov 2021Transcript PPT
-
Oct 2021TranscriptNotesPPT
-
Aug 2021Transcript PPT
-
Jun 2021Transcript PPT
-
Feb 2021Transcript PPT
-
Nov 2020Transcript PPT
-
Aug 2020Transcript PPT
-
Jun 2020TranscriptNotesPPT
-
Feb 2020Transcript PPT
-
Dec 2019TranscriptNotesPPT
-
Nov 2019TranscriptNotesPPT
-
Jul 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Nov 2018TranscriptPPT
-
Sep 2018TranscriptNotesPPT
Product Wise Revenue Mix
Insecticides: 53% of sales in FY vs 58% in FY21
Herbicides: 33% of sales in FY 22 vs 31% in FY21
Fungicides: 11% of sales in FY 22 vs 9% in FY21
PGR/Biologicals: 3% of sales in FY 22 vs 2% in FY21
The Co earned 55% of its revenue from Maharatna products and the remaining 45% from other branded products [1]
Segment-wise Revenue Split
B2C Segment: 65% of Net Revenue in FY22
B2B Segment: 26% of Net Revenue in FY22 [1]
Geography Wise Revenue Split as of FY22
South: 36%
East: 22%
West: 21%
North: 21% [1]
Brand
Some of its key brands are Pulsor, Green Label, Hercules, Kunoichi, Dominant, Lethal Gold, and KK Pro. The Co had partnered with Suniel Shetty, the Bollywood superstar, to build brand recognition. And in FY22, it has appointed Bollywood superstar Ajay Devgn as its brand ambassador to enhance its brand. [2]
New Products
The Co has recently launched four products: Hachiman, Oxim, Tory and Shinwa to further bolster its market share. [3]
Manufacturing Plants and Capacities
The Co. has six formulation plants , two technical synthesis plants, and one biological manufacturing plant. [4]
Its manufacturing capacity:
Liquid: 30,900 KLPA
Granules: 80,750 MTPA
Powder: 24,770 MTPA
Active Ingredient & Bulk: 13,800 MTPA [5]
It aims to increase its technical manufacturing capacity by nearly 50% at its Chopanki (Rajasthan) and Dahej (Gujarat) plants. [3]
Wide Dealer and Distribution Network
The Co has a distribution network of 380 SKUs, 6,000+ distributor connections, and 70,000+ dealer and retailer connections. [4]
Export
The Co exports its products to over 22 countries across the world. [4]
It as earned 9% of its total revenue through exports in FY22, compared to 4% in FY21. [6]
Special Tie-ups
The Co has entered into a JV with OAT Agrio Company Limited, Japan for innovation and the discovery of new molecules, as well as the marketing of its specialty products.
It has also tied up with Nissan Chemical Corporation (Japan), Momentive (USA), and Nihon Nohyaku Company Limited (Japan) for the marketing of its specialty products. [7]
Ban
In August 2018, the Ministry of Agriculture and Farmers Welfare prohibited four pesticides (contributing around Rs 160 Cr in FY18) being manufactured by the Co. However, continuous addition of new products mitigates the risk to a large extent. [8]
R&D
R&D as a percentage of revenue: <1% in FY22. [9]
It has 4 technologically advanced research and development units helping the company to develop a comprehensive range of agrochemical products. [4]
Patents
Till date the Company has filed 30 patents out of which 18 patents are already received. [9]